Sector
PharmaceuticalsOpen
₹410.6Prev. Close
₹406.6Turnover(Lac.)
₹2,173.01Day's High
₹433Day's Low
₹40852 Week's High
₹052 Week's Low
₹0Book Value
₹0Face Value
₹2Mkt Cap (₹ Cr.)
2,882.23P/E
65.77EPS
6.52Divi. Yield
0No Record Found
Y/e 31 Mar( In .Cr) | Mar-2015 | Mar-2014 | Mar-2013 | Mar-2012 |
---|---|---|---|---|
Equity Capital | 31.56 | 11.33 | 9.27 | 13.84 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 382.78 | 304.54 | 275.94 | 248.65 |
Net Worth | 414.34 | 315.87 | 285.21 | 262.49 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2015 | Mar-2014 | Mar-2013 | Mar-2012 |
---|---|---|---|---|
Revenue | 1,078.39 | 934.71 | 782.75 | 735.9 |
yoy growth (%) | 15.37 | 19.41 | 6.36 | 29.76 |
Raw materials | -628.31 | -541.93 | -484.95 | -468.66 |
As % of sales | 58.26 | 57.97 | 61.95 | 63.68 |
Employee costs | -114.11 | -95.26 | -76.74 | -59.52 |
Y/e 31 Mar( In .Cr) | Mar-2015 | Mar-2014 | Mar-2013 | Mar-2012 |
---|---|---|---|---|
Profit before tax | 44.36 | 27.94 | 23.63 | 37.27 |
Depreciation | -36.84 | -38.14 | -31.66 | -24.72 |
Tax paid | -4.47 | 7.27 | 2.64 | 15.78 |
Working capital | 101.47 | 46.43 | 68.92 | 13.89 |
Other operating items |
Y/e 31 Mar | Mar-2015 | Mar-2014 | Mar-2013 | Mar-2012 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 15.37 | 19.41 | 6.36 | 29.76 |
Op profit growth | 26.22 | 42.47 | 21.86 | 32.41 |
EBIT growth | 41.52 | 41.98 | -33.91 | 120.74 |
Net profit growth | 17.38 | 34.04 | -50.47 | -248.8 |
Particulars (Rupees in Crores.) | Mar-2015 | Mar-2014 | Mar-2013 | Mar-2012 | Mar-2011 |
---|---|---|---|---|---|
Gross Sales | 1,251.95 | 1,157.65 | 1,029.66 | 1,014.91 | 790.78 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 1,251.95 | 1,157.65 | 1,029.66 | 1,014.91 | 790.78 |
Other Operating Income | 64.68 | 55.04 | 55.11 | 51.47 | 43.65 |
Other Income | 20.08 | 22.94 | 18.06 | 40.91 | 21.96 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,698.35 | 129.24 | 4,07,155.15 | 1,181.05 | 0.8 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,549.7 | 71.05 | 1,47,295.24 | 594 | 0.54 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,444.25 | 25.07 | 1,16,664.33 | 1,438.15 | 0.9 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,183.9 | 59.03 | 1,07,673.27 | 485 | 0.88 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,458.1 | 52.42 | 1,01,358.17 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman
R Kannan
Managing Director
S Abhaya Kumar
Whole-time Director
S Vimal Kumar
Company Secretary
S Muralikrishna
Director
R Sundara Rajan
Whole-time Director
S Devendra
Director
N Subramanian
Director
Sunny Sharma
Whole-time Director
Arun Chandra Karmakar
Additional Director
Taru Mayur
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Shasun Pharmaceuticals Ltd Merged
Summary
Shasun Pharmaceuticals (Formerly known as Shasun Chemicals & Drugs Limited (SCDL)) was incorporated on 19th April 1976 as a private limited company under the name of Shasun Chemicals (Madras) Private Limited. SCDL is engaged in the manufacture of Active Pharmaceutical Ingredients (API) and drug products with a significant presence in the anti-inflammatory and anti-ulcerative therapeutic groups. In addition, the company has recently strengthened its offering in contract research, custom synthesis, contract manufacturing and contract formulation services through its acquisition of Rhodia Pharma Solutions and offers services and products to clients in US, Europe and Asia. Shasun headquartered in Chennai, India, operates world-class API facilities at Cuddalore and Puducherry in South India and Dudley in UK and Annan in Scottland. In the last few years Shasun has added a state-of-the-art research center in Chennai and a world class solid oral dosage formulation facility in Puducherry. The status of the company was converted from private limited to public limited in March of the year 1992. Subsequently, the name was changed to the present one Shasun Chemicals & Drugs Limited in October of the year 1993. SCDL came out with public issue in April of the year 1994 and in 1995, the company had signed a technical collaboration and marketing agreement with Nagase & Co., Japan, for the manufacture of S-Ibuprofen, a high value drug. During the identical year of 1995, SCDL had commissioned w
Read More
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.